Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesAlpha Cognition Inc

Alpha Cognition Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.62 USD -0.11 ( 1.26%)
Last update at 2026-11-11T21:27:00Z
VOLUME
124359
Market Cap
191.65M

Momentum Score

…

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.60
Low
9.00
High
52 Week Price Range
4.50
Low
10.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alpha Cognition Inc (NASDAQ: ACOG) is a small-cap company with limited public disclosure that appears to focus on developing therapies for cognitive disorders. Long-term growth drivers may include progress in clinical development, favorable regulatory outcomes, and partnerships or licensing that could support commercialization. Investors may find exposure to a focused neurotherapeutics niche and milestone-driven upside of interest.

Material risks include high probability of clinical or regulatory setbacks, ongoing financing needs that could dilute shareholders, thin trading liquidity, and intense competition in neurodegenerative therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.73
Dividend Yield
-
Revenue TTM
15.26M
Revenue Per Share
0.74
Gross Profit TTM
13.79M
Debt / Equity
0.02
ROE
-49.53%
Net Debt
-66.11M
ROCE
-32.18%
Diluted EPS TTM
-0.99

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -20.67M -14.64M -13.77M -12.11M -19.55M
Net income -20.67M -14.64M -13.77M -12.11M -19.55M
Selling general administrative 27.23M 7.22M 4.67M 4.02M 3.28M
Selling and marketing expenses 1.81M 0.10M 0.02M 0.03M 0.10M
Gross profit 8.30M -0.08M - - -
Reconciled depreciation 0.06M 0.08M 0.08M 0.09M 0.09M
Ebit -22.72M -14.45M -13.70M -11.94M -19.02M
Ebitda -22.66M -14.37M -13.62M -11.85M -18.93M
Depreciation and amortization 0.06M 0.08M 0.08M 0.09M 0.09M
Operating income -22.66M -11.86M -9.62M -13.47M -11.57M
Other operating expenses 32.88M 11.86M 9.62M 13.47M 11.57M
Interest expense - 0.19M 0.07M 0.17M 0.53M
Interest income 1.90M 0.16M 0.01M 0.00M 0.00M
Net interest income 1.90M -0.48M -0.06M -0.17M -0.53M
Total revenue 10.22M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 30.97M 11.86M 9.62M 13.47M 11.57M
Cost of revenue 1.92M 0.08M - - -
Total other income expense net 1.99M -2.78M -4.15M 1.35M -7.98M
Net income from continuing ops -20.67M -14.64M -13.77M -12.11M -19.55M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 79.73M 50.74M 2.45M 2.95M 12.88M
Intangible assets 0.39M 0.41M 0.53M 0.61M 0.70M
Other current assets 3.55M 0.84M 0.37M 0.25M 0.87M
Total liab 17.20M 9.27M 7.16M 4.27M 3.85M
Total stockholder equity 62.53M 41.46M -4.71M -1.32M 9.03M
Other current liab - 1.57M 1.39M 0.83M 0.27M
Common stock 133.89M 99.13M 50.35M 40.26M 40.01M
Capital stock 133.89M 99.13M 50.35M 40.26M 40.01M
Retained earnings -97.11M -76.29M -63.35M -49.99M -38.03M
Good will 0.39M - - - -
Cash 66.11M 48.55M 1.49M 2.08M 11.30M
Total current liabilities 9.13M 3.35M 2.62M 4.06M 1.80M
Current deferred revenue 0.15M - 0.01M - -
Net debt -66.11M -47.63M -0.27M -0.87M -10.23M
Short term debt - 0.91M 1.22M 1.21M 1.08M
Short long term debt - 0.91M 1.22M 1.21M 1.08M
Short long term debt total - 0.91M 1.22M 1.21M 1.08M
Other stockholder equity 25.85M 18.72M - -0.00M -
Total current assets 79.01M 50.25M 1.92M 2.33M 12.17M
Net receivables 4.24M 0.25M 0.06M - -
Inventory 5.12M 0.62M 0.00M - -
Accounts payable 8.98M 0.87M 0.48M 2.02M 0.45M
Accumulated other comprehensive income -0.10M -0.10M 8.29M 8.41M 7.05M
Non currrent assets other - 0.05M - - -
Non current assets total 0.72M 0.49M 0.53M 0.62M 0.71M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M 0.00M -0.00M 0.46M
Total cashflows from investing activities -0.29M -0.03M - -0.00M 0.46M
Net borrowings -0.91M 4.25M -0.06M 0.00M 0.00M
Total cash from financing activities 38.21M 54.85M 8.16M 0.02M 14.88M
Net income -20.67M -14.64M -13.77M -12.11M -19.55M
Change in cash 17.54M 47.07M -0.59M -9.22M 5.38M
Begin period cash flow 48.56M 1.49M 2.08M 11.30M 5.93M
End period cash flow 66.11M 48.56M 1.49M 2.08M 11.30M
Total cash from operating activities -20.38M -7.76M -8.73M -9.24M -9.88M
Issuance of capital stock 34.32M 56.54M 9.22M 0.00M 13.65M
Depreciation 0.06M 0.08M 0.08M 0.09M 0.09M
Other cashflows from investing activities -0.29M - - - -0.05M
Dividends paid - - 0.00M 0.00M 0.00M
Change to inventory -4.51M -0.62M 0.00M - -
Change to account receivables -4.24M 0.00M - - -
Other cashflows from financing activities 0.04M -5.93M -1.01M 0.02M 1.23M
Capital expenditures 0.29M 0.03M 0.00M 0.00M 0.06M
Change in working capital -4.62M -0.24M -1.56M 2.73M -0.29M
Stock based compensation 4.92M 0.98M 2.37M 1.70M 1.79M
Other non cash items -0.07M 6.06M 4.15M -1.65M 8.07M
Free cash flow -20.67M -7.78M -8.73M -9.25M -9.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACOG
Alpha Cognition Inc		 -0.11
1.26%		 8.62 - 26.88 12.56 3.55 9.19 -1.57
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Alpha Cognition Inc

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

1452 Hughes Street, Grapevine, TX, United States, 76051

858 344 4375

https://www.alphacognition.com

71

Name Title Year Born
Mr. Michael E. McFadden B.B.A. CEO & Director 1967
Ms. Lauren D'Angelo M.B.A. Chief Operating Officer 1978
Mr. Kenneth Anthony Cawkell B.A., LL.B. Founder, Consultant, Corporate Secretary & Director 1951
Mr. Henry Du CPA VP of Finance & Accounting and Interim CFO 1979
Dr. Denis G. Kay M.Sc., Ph.D. Chief Scientific Officer 1957
Mr. Timothy Ayers Head of Compliance NA
Ms. Amy Kincaid Executive Director, Head of Marketing & Commercial Strategy NA
Mr. Jack Kelly Executive Director & Head of Market Access NA
Mr. Henry H. Du CPA VP of Finance & Accounting and Interim CFO 1979
Ms. Christine Reveal Vice President of Marketing & Commercial Strategy NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…